Edition:
Deutschland

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.85USD
22:00 Uhr
Change (% chg)

$0.03 (+3.66%)
Prev Close
$0.82
Open
$0.84
Day's High
$0.86
Day's Low
$0.82
Volume
22,539
Avg. Vol
138,959
52-wk High
$5.54
52-wk Low
$0.62

TROV.OQ

Chart for TROV.OQ

About

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 1 analysts

Overall

Beta: 0.41
Market Cap(Mil.): $30.56
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

BRIEF-Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

* Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

BRIEF-Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075

* Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor

BRIEF-CVI Investments Inc reports 5.7 percent passive stake in Trovagene as of July 13 - SEC filing

July 24 CVI Investments Inc. Reports 5.7 Pct Passive Stake In Trovagene Inc

BRIEF-Sabby Management reports 5.70 percent passive stake in Trovagene

* Sabby Management LLC reports 5.70 percent passive stake in Trovagene Inc as of July 13 - sec filing Source text : http://bit.ly/2uwdR7Z Further company coverage:

BRIEF-Trovagene announces $7.1 million registered direct offering

* Trovagene announces $7.1 million registered direct offering

BRIEF-Trovagene announces agreement with Novogene

* Trovagene announces agreement with Novogene for NextCollect in China

BRIEF-Trovagene regains compliance with NASDAQ listing requirements

* Trovagene Inc regains compliance with NASDAQ listing requirements Source text for Eikon: Further company coverage:

BRIEF-Trovagene engages PRA Health Sciences to conduct phase 1b/2 trial of PCM-075

* Trovagene engages leading cro in aml to conduct phase 1b/2 trial of pcm-075 Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.82%
Rohstoffe +0.59%
Industrie +0.62%
Konjunktur abhängige Waren & Dienstleistungen +0.03%
Konjunktur unabhängige Waren & Dienstleistungen +0.36%
Finanzindustrie +0.98%
Pharma +1.27%
Technologie +0.28%
Telekommunikation +0.15%

Nachrichten aus der Wirtschaft